famvir 500 mg tabletti, kalvopäällysteinen
phoenix labs - famciclovir - tabletti, kalvopäällysteinen - 500 mg - famsikloviiri
valavir 500 mg tabletti, kalvopäällysteinen
orion corporation - valaciclovir hydrochloride - tabletti, kalvopäällysteinen - 500 mg - valasikloviiri
valtrex 250 mg tabletti, kalvopäällysteinen
glaxosmithkline oy - valaciclovir hydrochloride - tabletti, kalvopäällysteinen - 250 mg - valasikloviiri
valaciclovir ratiopharm 500 mg tabletti, kalvopäällysteinen
teva sweden ab - valaciclovir hydrochloride - tabletti, kalvopäällysteinen - 500 mg - valasikloviiri
priorix tetra injektiokuiva-aine ja liuotin, liuosta varten, esitäytetty ruisku
glaxosmithkline biologicals sa - measles virus (schwarz), live attenuated, mumps virus (rit 4385), live attenuated, rubella virus (wistar ra 27/3), live attenuated, varicella zoster virus (oka), live attenuated - injektiokuiva-aine ja liuotin, liuosta varten, esitäytetty ruisku - tuhkarokko-sikotauti-vihurirokko-vesirokkorokote
priorix tetra injektiokuiva-aine ja liuotin, liuosta varten
glaxosmithkline biologicals sa - measles virus (schwarz), live attenuated, mumps virus (rit 4385), live attenuated, rubella virus (wistar ra 27/3), live attenuated, varicella zoster virus (oka), live attenuated - injektiokuiva-aine ja liuotin, liuosta varten - tuhkarokko-sikotauti-vihurirokko-vesirokkorokote
valaciclovir bluefish 500 mg tabletti, kalvopäällysteinen
bluefish pharmaceuticals ab - valacicloviri hydrochloridum monohydricum - tabletti, kalvopäällysteinen - 500 mg - valasikloviiri
rybrevant
janssen-cilag international n.v. - amivantamab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
tecovirimat siga
siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antiviraalit systeemiseen käyttöön - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 ja 5. tecovirimat siga should be used in accordance with official recommendations.